<DOC>
	<DOCNO>NCT03057028</DOCNO>
	<brief_summary>Pulmonary arterial hypertension ( PAH ) result right ventricular failure death . Anakinra use patient leave sided heart failure , present study look determine anakinra safe effective patient PAH . To accomplish goal , plan evaluate exercise improvement ( assessed cardiopulmonary exercise test ) 10 patient PAH anakinra .</brief_summary>
	<brief_title>Pilot Study Safety Efficacy Anakinra Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>Patients pulmonary arterial hypertension undergo cardiopulmonary exercise testing ( CPET ) baseline 2 week . After initial CPET , patient receive anakinra daily injection 2 week . Patients instructed use anakinra initial visit . Our primary outcome difference exercise capacity patient PAH , measure maximal uptake oxygen CPET .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>age 18 functional class II III symptom right ventricular failure despite optimal PAH therapy mean pulmonary artery pressure &gt; 25mmHg previous right heart catheterization pulmonary arterial wedge pressure &lt; 15mmHg previous right heart catheterization pulmonary vascular resistance &gt; 3 wood unit previous right heart catheterization PAH due connective tissue disease angina electrocardiograph change limit maximum exertion cardiopulmonary exercise test baseline EKG change limit ability detect ischemia recent ( &lt; 14 day ) use antiinflammatory drug ( include NSAIDs ) , chronic inflammatory disorder , malignancy , active infection , comorbidity limit survival ability complete study sever kidney dysfunction ( eGFR &lt; 30mL/min ) thrombocytopenia ( &lt; 50,000/mm3 ) , neutropenia ( absolute neutrophil count &lt; 1500/mm3 ) refusal woman childbearing potential use medically acceptable form birth control history hypersensitivity anakinra E. coli product latex rubber allergy inability give inform consent nonEnglish speaking</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>